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Reduced mu opioid receptor availability in
schizophrenia revealed with [11C]-carfentanil
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Negative symptoms, such as amotivation and anhedonia, are a major cause of functional
impairment in schizophrenia. There are currently no licensed treatments for negative
symptoms, highlighting the need to understand the molecular mechanisms underlying them.
Mu-opioid receptors (MOR) in the striatum play a key role in hedonic processing and reward
function and are reduced post-mortem in schizophrenia. However, it is unknown if mu-opioid
receptor availability is altered in-vivo or related to negative symptoms in schizophrenia. Using
[11 C]-carfentanil positron emission tomography (PET) scans in 19 schizophrenia patients and
20 age-matched healthy controls, here we show a significantly lower MOR availability in
patients with schizophrenia in the striatum (Cohen’s d= 0.7), and the hedonic network. In
addition, we report a marked global increase in inter-regional covariance of MOR availability
in schizophrenia, largely due to increased cortical-subcortical covariance.
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Schizophrenia affects about one in 100 people and is aleading cause of disease burden1. Patients with schizo-phrenia commonly experience negative symptoms, which
include amotivation, anhedonia and asociality. Moreover, nega-
tive symptoms are associated with poor functional outcomes2.
Antipsychotics only marginally improve negative symptoms3, and
there are no currently licensed treatments specifically for negative
symptoms. In view of this, and the marked impact of negative
symptoms on recovery, there is considerable interest in identi-
fying potential treatment targets for these symptoms. However,
the neurobiological mechanisms underlying negative symptoms
remain unclear4.
Impairments in hedonic function are thought to be a key
mechanism underlying negative symptoms2, conceptualised as
reduced motivation to pursue reward (anticipatory anhedonia)
and reduced hedonic response to reward itself (consummatory
anhedonia). Studies assessing these features in schizophrenia have
reported deficits in either consummatory5, or anticipatory6, or
both components of hedonic function7.
Converging lines of evidence indicate that MOR play a central
role in hedonic function. Specifically, MOR knock out mouse
models show anhedonic phenotypes such as decreased condi-
tioned social place preference8, and reduced nose pokes for
sucrose pellets9. Moreover, pharmacological MOR blockade
induces conditioned place aversion10 and reduces social novelty
preference11. Deficits in both sucrose preference12 and pro-
gressive ratio response paradigms9 suggest that mu-opioid system
is involved in both the anticipatory and consummatory compo-
nents of the anhedonic response. In contrast, MOR stimulation
increases motivation to seek reward13,14, and increases food
palatability15. Consistent with these findings, human studies
report blockade of MOR decreases the pleasantness of palatable
foods16 and sexual stimuli17, whilst pharmacological stimulation
of the opioid system increases the hedonic evaluation and moti-
vation for viewing rewarding images18.
The MOR system also modulates social interaction. Specifi-
cally, MOR knockout pups emit fewer ultrasonic vocalisations
when removed from their mother, suggesting reduced maternal
attachment behaviour19. Human molecular imaging studies using
[11C]-carfentanil, a MOR agonist tracer, have shown that MOR
activation in the amygdala, insula, and striatum are linked to
increased social acceptance and interaction20. In summary, both
preclinical and human studies show a potential role of MOR in
mediating anhedonia, amotivation and asociality.
Opioid dysregulation in schizophrenia was first suggested in
the 1980s21 based on findings of elevated beta-endorphin levels in
the cerebrospinal fluid of schizophrenia patients22–24 and clinical
studies of naloxone, a MOR antagonist treatment showing a
reduction of psychotic symptoms in some patients25. Post-
mortem studies have found elevated MOR mRNA levels in the
frontal cortex of patients26, but lower binding of the MOR
selective agonist, [3H]-DAMGO, in the cingulate gyrus and
caudate-putamen of schizophrenia patients who died by suicide
compared to healthy controls and patients who had died by non-
suicide causes27. The inconsistency in the findings of post mor-
tem studies could be due to confounders such as the inclusion of
more people who had died by suicide in the patient group given
that brain MOR mRNA and protein levels have been found to be
altered in suicide victims compared to healthy controls27–29.
Despite the preclinical, human studies and evidence from post-
mortem and peripheral measures of the potential role of MOR in
schizophrenia, there have not been, to our knowledge, any pre-
vious PET studies of MOR availability in vivo in schizophrenia.
[11C]-carfentanil is a selective MOR tracer with over two orders
of magnitude higher affinity for MOR than other receptors [Ki(μ)
= 0.024 nM, Ki(δ)= 3.28 nM, Ki(κ)= 43.1nM30], shows
excellent reproducibility (variability < 10%, intraclass correlation
coefficients >0.93 in test-retest studies)31 and kinetic properties,
making it a good tracer to evaluate the MOR in vivo in neu-
ropsychiatric disorders30.
Here we show that patients with schizophrenia have reduced
MOR availability in striatum and brain regions implicated in
hedonic responses compared to healthy controls. In addition, we
report a highly significant global increase in MOR connection
strength in schizophrenia patients relative to controls, largely due
to increased cortical-subcortical connectivity.
Results
Subject charecteristics. Twenty individuals with schizophrenia
and 20 healthy control subjects were studied. One patient had a
structural abnormality on the MRI scan and was excluded from
further analysis. Demographic details for all participants are given
in Table 1. All patients were taking an antipsychotic at the time of
the scan (listed in Supplementary Table 1). There was no sig-
nificant difference between groups in age, sex, radioactive dose
and injected mass per body weight (μgm/kg) received. There were
more smokers in the patient group compared to healthy control
group, and patients smoked significantly more cigarettes per day
than controls (number of cigarettes smoked per day (mean ±
SEM): patients= 8.2 ± 2.1 vs. controls= 0.9 ± 0.6; p < 0.001).
There were significant group differences in anhedonia and BMI,
with higher anhedonia ratings in patients (Table1). There was no
significant difference in the rs1799971 genotype frequency between
groups. The gene frequency in our sample is consistent with
previous studies which reported a A:A genotype frequency of 75%32.
Region of interest analysis. The Region of interest (ROI) analysis
showed significantly lower MOR availability in the striatum of
patients with schizophrenia relative to controls (patients vs. con-
trols (mean ± SEM): 1.54 ± 0.06 vs. 1.7 ± 0.05, Cohen’s d= 0.7 t=
−2.2, df (37), p= 0.037) (Fig. 1). These changes were significant in
the dorsal striatum (patients vs. controls (mean ± SEM): 1.35 ±
0.06 vs. 1.53 ± 0.05, p= 0.03), but no significant differences
were seen in the ventral striatum (patients vs. controls (mean ±
SEM): 2.6 ± 0.08 vs. 2.69 ± 0.07, p= 0.45). There was no
correlation between striatal MOR availability and negative
symptom severity (Supplementary Fig. 1; PANSS-negative symp-
tom subscale- r: 0.07, p= 0.78, SANS-25 total score- r: −0.151,
p= 0.54), or social, physical, anticipatory and consummatory
anhedonia measures in patients and controls (all p > 0.05). Simi-
larly, there was no association between dorsal or ventral striatal
MOR availability and negative symptom or anhedonia severity
(all p > 0.05). Secondary analysis revealed a significant effect
of both group (F (5, 222)= 334.5, p < 0.05) and ROI
(F (1, 222)= 5.654 p < 0.05) on BPND measures in the hedonic
network (Fig. 2). The group × ROI interaction was not significant
(F (5, 222)= 0.2167, p > 0.05).
In view of the significant group differences in BMI and
smoking, we conducted an exploratory analysis of the relationship
between them and MOR. This showed there was no significant
correlation between striatal MOR availability and BMI in patients
(Pearson r=−0.35, p= 0.1) or controls (Pearson r=−0.33, p=
0.15). There was no association between number of tobacco
cigarette smoked per day and MOR availability in striatum
(patients: r=−0.047 p= 0.85; controls: r= 0.27, p= 0.25).
The area under the curve of the standardised uptake values for
the occipital cortex did not differ between the groups (Supple-
mentary Fig. 2, p > 0.05), consistent with the assumption of no
difference in reference tissue MOR signal between the groups. To
explore if antipsychotic treatment could influence our MOR
findings, we calculated the chlorpromazine equivalent (CPZ
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equivalent) dose of antipsychotic treatment in all patients using
the method described by Leucht et al.33,34, and investigated if
there was a relationship between antipsychotic dose and MOR.
There was no association between striatal MOR availability and
antipsychotic dose (r= 0.06, p= 0.82) (Supplementary Fig. 3).
Furthermore, none of the antipsychotics has significant affinity
for MOR (see Supplementary Table 2 for affinities).
There was no significant difference in the total grey matter
volume between groups (patients vs. control: mean ± SEM (mm3)
1171573 ± 16661 vs. 1217443 ± 21157, respectively, p= 0.1).
Moreover, there were no significant differences in the volume
of the striatum between groups (patients vs. controls: mean ±
SEM (mm3) 13019 ± 302 vs. 12937 ± 327, respectively, p= 0.86).
There was a significant difference between groups in the volumes
of the regions in the hedonic network (Supplementary Table 3).
However, there were no relationships between grey matter
volume and MOR binding potential in the striatum or any of
the other regions of interest (all r −0.2 to 0.3, p > 0.05).
Mu opioid receptor covariance network analysis. Z-matrices for
both patients and controls are shown in Fig. 3. Binding potentials
throughout the cortex show moderate to high correlations with
binding potentials in other cortical regions in both groups.
However, qualitatively, the schizophrenia group shows more
regions with high positive correlations relative to healthy controls
(see Fig. 3). Quantitatively, we found a highly significant (p <
0.00001) increase in the connection strength of MOR BPND in
1791 out of 7750 edges in schizophrenia patients relative to
healthy controls with a threshold of p < 0.05 corrected for mul-
tiple comparisons using the network-based statistics algorithm
(see Fig. 4a). This represents MOR correlations across the whole
brain region, suggesting a global increased connectivity in
patients compared to controls. To investigate the most sig-
nificantly different networks between groups, we applied a more
constrained primary threshold of p < 0.001 (corrected for multiple
comparison using the network-based statistics algorithm). This
identified increased MOR BPND covariation in 99 out of 7750
edges in the schizophrenia patient group compared to controls in
a cerebello-thalamo-cortical covariance network (see Fig. 4b).
Discussion
MOR availability was reduced in vivo in the striatum with a large
effect size (Cohen’s d= 0.7) in schizophrenia patients compared
to healthy controls, consistent with our main hypothesis. Our
secondary analyses showed significantly reduced mu-opioid
receptor availability across other brain regions involved in
hedonic processes, comprising the orbitofrontal cortex, cingulate
cortex, insular cortex, midbrain, and amygdala, in schizophrenia.
Furthermore, the covariance network analysis showed
Table 1 Demographics of study subjects
Schizophrenia patients (n= 19) (mean ± SEM) Controls (n= 20) p-value
Age (years) 35.1 ± 2.1 36.85 ± 2.7 0.61
Gender (male/female) 19/0 18/2 0.256
Injected radioactivity (MBq) 198.6 ± 9.1 198.5 ± 9.7 0.9
Injected mass per body weight (µgm/kg) 0.023 ± 0.003 0.024 ± 0.003 0.6
BMI (kg/m2) 29.3 ± 1 25.2 ± 0.8 0.003*
Mean age at onset (years) 23.05 ± 1.2 n/a n/a
Mean duration of illness (years) 11.3 ± 2.2 n/a n/a
PANSS n/a n/a
Positive 14.5 ± 0.4
Negative 21.4 ± 1
General 26.5 ± 0.8
Total 62.5 ± 1.9
SANS-25 55.7 ± 5 n/a n/a
Revised social anhedonia scale 17.6 ± 1.9 9.8 ± 1.7 0.004*
Revised physical anhedonia scale 23.3 ± 2.8 13.3 ± 3 0.017*
Temporal experience pleasure scale
Anticipatory pleasure scale 38.9 ± 2.6 43.2 ± 2 0.2
Consummatory pleasure scale 28.3 ± 2.3 35 ± 1.7 0.025*
Genotyping rs1799971-
A:A 16 15 0.9
G:A 3 4
G:G 0 1
Calgary depression scale total score 7.7 ± 1.5 n/a n/a
Number of cigarette smoked per day 8.2 ± 2.1 0.9 ± 0.6 0.001*
There were no significant differences in demographics other than for body mass index (BMI) and number of cigarettes smoked per day
n/a not applicable; *p < 0.05
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Fig. 1 Striatal mu opioid receptor (MOR) availability in schizophrenia
patients and controls showing means (horizontal line) and standard error
(error bars). There was a significant reduction in the MOR availability in
schizophrenia patients (cohen’s d= 0.7; *p < 0.05)
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significantly elevated cortical-to-subcortical correlations between
mu-opioid receptor levels in schizophrenia patients relative to
controls. However, MOR availability was not linked to negative
symptom or anhedonia severity ratings.
Our findings extend post-mortem findings of reduced MOR
density measured with DAMGO, a MOR selective agonist, by
showing reduced MOR availability in vivo and without the
potential confound of suicide27. MOR mRNA levels have been
reported to be elevated in the frontal cortex of patients with
schizophrenia26. Studies in healthy volunteers have shown that
MOR levels measured with PET are not closely correlated with
mRNA levels, likely reflecting the fact the MOR undergoes post-
transcriptional modification35. Thus, our findings taken with
evidence of elevated MOR mRNA levels in the frontal cortex of
patients26, could suggest there is increased post-transciptional
modification and/or internalisation or breakdown of mu-opioid
receptors in schizophrenia.
To our knowledge, this is the first study investigating MOR
availability in vivo in schizophrenia. In our sample, all subjects
were treated with antipsychotics. However, none of the anti-
psychotics taken by the patients has significant affinity for the
MOR (all Ki values > 1000)36–39. Moreover, it is important to
note that non-human primate studies show that neither halo-
peridol nor olanzapine leads to appreciable alterations in the
MOR availability, indicating that antipsychotic treatment does
not significantly alter MOR26. Thus, it is unlikely that
antipsychotic treatment is a significant confounder. Nevertheless,
several preclinical studies have shown that alteration in dopa-
minergic activity can affect opioidergic neurotransmission40.
Future studies in drug naïve subjects are needed to address this
potential confounding effect.
We used the SRTM model with the occipital cortex as a
reference region to estimate MOR availability. We used lower
layers of the occipital cortex as the reference region as this has
negligible MOR levels and has been validated by previous stu-
dies41,42. In addition, the area under the curve of the standardised
uptake values for the occipital cortex, representing non-specific
tracer accumulation in this region, did not differ between the
groups, indicating that there are no significant group differences
in tracer binding in this region.
Previous studies have reported altered MOR availability in
morbidly obese subjects with BMI values of 38–4243. In our
cohort, patients had a higher BMI (range 17.5–38) compared to
controls (range 18.5–35), although not in the morbidly obese
range. Moreover, there was no correlation between BMI and
striatal MOR availability in our samples, suggesting the BMI
difference is unlikely to account for our findings. Nevertheless, it
would be useful in future studies to investigate this further.
Studies have shown that alcohol, opioid, stimulant, and tobacco
smoking could affect the opioid signaling44,45. However, none of
our patients and controls met criteria for present or past sub-
stance use disorder, indicating this is unlikely to be a confound
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Fig. 2 [11C]-carfentanil binding potentials in the hedonic network of healthy controls and schizophrenia patients (mean ± SEM). There was a significant
group effect on BPND measures in the hedonic network, with lower levels in patients (*p < 0.05)
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for the MOR availability measurements. Although, patients
smoked more cigarretes than controls, there was no correlation
between MOR availability and a number of tobacco cigarettes
smoked, suggesting smoking is not a major confound. However,
given that tobacco smoking may affect opioid signalling44, it is
possible that group differences in cigarette smoking could have
influenced our findings.
There was no significant difference in the total gray matter and
striatal volume between patients and controls. Further, there was
no association between gray matter volume and BPND, suggesting
partial volume effects are unlikely to be a significant confounder.
However, there was a difference in the volumes between groups in
the regions in the hedonic network, which could indicate
that partial volume effects contribute to our findings in these
regions. Notwithstanding this, we did not find any significant
relationships between gray matter volume in the striatum or any
other region of interest, indicating that partial volume effects are
unlikely to have had a major effect on our findings.
Previous post-mortem studies have reported no alteration in
delta and kappa opioid receptors in schizophrenia26. Combined
with the high selectivity of [¹¹C]-carfentanil for the MOR (Ki=
0.0024 nM) over delta opioid (Ki= 3.28 nM) and kappa opioid
receptors (Ki= 43.1 nM), our data indicate a lower MOR avail-
ability in schizophrenia patients46.
The reduced BPND could be due to receptor down-regulation,
or neuronal loss30, whilst our finding of increased cross-
correlations between MOR levels across the brain in schizo-
phrenia suggests a global dysregulation. The downregulation of
the MOR could be due to long-term overstimulation of MOR by
beta-endorphins and Leu-enkephalin, which both have high
Primary threshold P < 0.05a b Primary threshold P < 0.001
Fig. 4 Regions identified as showing significantly greater covariance in schizophrenia compared to healthy controls. Using a primary threshold of p < 0.05
(false discovery rate corrected), a global increase in connectivity was shown in schizophrenia (left-hand side). A more conservative (p < 0.001 false
discovery rate corrected) threshold identified the most significant components to be in a cerebello-thalamo-cortical network (b, right-hand side)
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Fig. 3 Matrices showing region-by-region correlations, represented as Z scores, throughout the whole brain (125 ROIs) by group. X and Y axes represent
BPND values across the 125 ROIs defined by the Clinical Imaging Centre (CIC) atlas. a shows data for controls. b shows data for patients. The colour bar
represents the strength of correlation expressed as a Z-score (red= high positive correlation, blue= high negative correlation)
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affinity for MOR (Ki values of 0.3 and 1, respectively)47. This is
consistent with the findings of elevated beta-endorphin23 and
enkepalin48 levels in CSF from schizophrenia patients, although
post mortem studies have not reported alteration in enkephalin
mRNA levels in schizophrenia26,49. MOR activation inhibits
release of GABA in the cortex50 and, in the striatum, leads to
dopamine release51 and is associated with increased dopamine
synthesis capacity52. Thus, increased beta-endorphin levels could
lead to reduced cortical inhibition, leading to cognitive impair-
ments, and striatal dopamine disinhibition in schizophrenia,
leading to psychotic symptoms due to dopamine dysregulation53.
However, as we did not measure beta-endorphin levels or
dopamine function, it needs to be determined if lower MOR
availability in the striatum in schizophrenia is due to elevated
beta-endorphin levels or linked to dopamine dysfunction. [11C]-
carfentanil is sensitive to endogenous opioid levels, which com-
pete with the tracer to reduce its binding to the MOR42,54. Thus,
the reduction in MOR BPND could be due to either reduced
receptor availability or increased endogenous opioid release, or a
combination of both. Future studies, using pharmacological
challenges that release endogenous opioids, such as ampheta-
mine, would be useful to determine if the lower levels of [11C]-
carfentanil binding we observed are due to altered endogenous
opioid release or reduced MOR levels41,42.
It is surprising that there was no significant association
between MOR availability and either total negative symptoms or
anhedonia severity (social, physical, anticipatory and con-
summatory anhedonia), given the lower MOR availability in
patients. Our secondary analyses found that MOR availability was
significantly lower in the dorsal but not ventral striatum in
patients relative to controls, suggesting that the finding of lower
striatal MOR in patients was driven by differences in the dorsal
striatum. Striatal MOR blockade reduces the motivation to seek
food13 and sexual pleasure in animals55. In addition, there is
some evidence that this particularly involves the dorsal striatum,
including findings that endogenous opioids released in the dorsal
striatum during food consumption are associated with motivation
to eat but not with the hedonic orofacial response to food13 and
blockade of MOR in the dorsal striatum abolished formation of
partner preference without evoking partner aversion55. In con-
trast, ventral striatal MOR blockade has generally been linked to
anhedonia56. Thus, these findings indicate that our results of
lower dorsal striatal MOR availability may contribute to the
amotivation rather than anhedonic component of negative
symptoms in schizophrenia, and the lack of major differences in
ventral striatal MOR availability could indicate that another
mechanism underlies anhedonia seen in schizophrenia. However,
as we did not measure motivation, the association between dorsal
striatal MOR and amotivation requires testing in patients.
Alternatively, the lack of association between negative symptoms
and MOR could indicate they are linked to other neuro-
transmitter dysfunction rather than MOR2,57,58, or, given that our
patients had been ill for a number of years, that MOR alterations
underlie the development of negative symptoms but not their
maintenance in chronic patients.
The mean PANSS in our cohort was 60 and the mean PANSS-
negative symptom score in our cohort was 21, and the highest was
30 (total possible score= 49). The total severity rating is lower than
typically reported in studies of acute relapses, but is consistent with
recent randomised control trials of treatments for negative symp-
toms, where mean PANSS total scores were 47–80 and mean
negative scores were 17–2259–61. Consistent with these studies and
recommendations for studies of negative symptoms, we recruited
subjects with predominant negative symptom without acute posi-
tive symptoms (no more than PANSS positive subscale score of 4)
as these can confound the assessment of negative symptoms62.
Thus, our study, in common with others in the literature59–61,
largely recruited patients with moderate symptom severity, which
could affect generalisability to patients with more severe symptoms.
It has been suggested that negative symptoms can be con-
sidered as primary, that is intrinsic to the disease process, or
secondary to other factors such as acute psychosis, comorbid
depression, antipsychotic effects or other factors63. We excluded
marked psychosis and comorbid depression in our sample,
indicating that negative symptoms are unlikely to be due to these
factors. We also applied the deficit schizophrenia criteria, which
are used to identify patients with schizophrenia showing primary
and enduring negative symptoms64. This suggests the negative
symptoms in our patient sample are likely to be predominantly
primary in nature. However, we can not exclude some con-
tribution from secondary factors in the negative symptoms in our
patients, which, if these have alternative mechanisms, may have
reduced our ability to detect a relationship between MOR and
negative symptoms. Future longitudinal studies in early course,
untreated patients would be helpful to confirm our findings in
patients at the onset of negative symptoms.
The application of the network-based statistical analysis to
MOR is, to our knowledge, novel in both healthy volunteers and
schizophrenia. Nevertheless, we applied an approach that is well-
established in the fMRI literature and has been applied to PET
studies of other receptors65–67, a conservative p-value threshold
(p < 0.001) and false discovery rate correction to control the type-
1 error rate. This analysis found stronger [11C]-carfentanil BPND
correlations across cerebello-thalamo-cortical regions in patients
compared to healthy control. There are two main mechanisms
that could account for this. One is it could be a consequence of
increased CSF beta-endorphin levels in schizophrenia23. Beta-
endorphin synthesised in pro-opiomelanocortin (POMC) neu-
rons in the hypothalamus diffuses through cerebrospinal fluid to
act on MOR throughout the brain by volume transmission68.
Thus, given that [11C]-carfentanil is displaced by endogenous
MOR ligands, increased brain beta-endorphin levels in schizo-
phrenia could lead to reduced variability of MOR, as is seen with
exogenous opiate block, which will increase inter-regional cor-
relations as the range of possible BPND values is lower69. Alter-
natively, the higher inter-regional correlations could be due to
altered genetic regulation of MOR expression. Supporting this, a
preclinical study has shown that deletion of the mu opioid
receptor gene (Oprm1) results in disrupted whole brain resting
state functional connectivity70. Notwithstanding this evidence, it
is important to recognise that the physiological significance of the
increased MOR covariance network in schizophrenia remains to
be determined. Combined MOR and functional imaging studies
in patients and healthy volunteers would be useful to test this.
In conclusion, mu opioid receptor availability is reduced in the
striatum and other brain regions involved in hedonic processes
and shows increased cortical-subcortical correlations in schizo-
phrenia. However, it is not associated with negative symptom
severity or anhedonia measures. These findings provide in vivo
evidence for altered brain opioid signaling in schizophrenia.
Methods
Subject recruitment. The study protocol was approved by London-Camberwell St
Giles Research Ethics Committee and approval to administer radioactive material
was granted by Administration of Radioactive Substances Advisory Committee
(ARSAC, UK). All participants provided written informed consent to participate
after receiving a description of the study.
We recruited 20 patients with schizophrenia from secondary mental health
services. All patients met DSM-IV criteria for schizophrenia. They were required to
have a minimum score ≥4 on atleast one domain of positive and negative symptom
scale (PANSS) negative symptom sub-scale71 OR two or more negative symptoms
with a score ≥3 on the PANSS-negative symptom sub-scale to ensure current
negative symptoms. All patients were required to meet criteria for deficit syndrome
defined, in accordance with guidelines64,72, as (a) the presence of at least two out of
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six of the following negative symptoms: restricted affect (referring to observed
behaviours rather than to the patient’s subjective experience); diminished
emotional range (i.e., reduced range of the patient’s subjective emotional
experience); poverty of speech; curbing of interests; diminished sense of purpose;
diminished social drive; and (b) a combination of two or more of the above
symptoms have been present for the preceding 12 months and were always present
during periods of clinical stability; and (c) the above symptoms are not secondary
to other factors, including anxiety, drug effects, psychotic symptoms, mental
retardation, or depression; and (d) the patient meets DSM criteria for
schizophrenia. The secondary factors associated with negative symptoms were
excluded based on clinical interview. All patients were required to be on a stable
dose of an antipsychotic for at least four weeks before the scan (see Supplementary
Table 1 for a list of treatments).
Twenty healthy volunteers were recruited from the same local catchment area
through public advertisement. Inclusion criteria included no psychiatric morbidity
as assessed by the Structured Clinical Interview for DSM IV (SCID), and no family
history of psychosis. Exclusion criteria for all subjects were: history or current
substance use disorder (other than to tobacco) as assessed by clinical interview,
history of head injury or neurological abnormality, present or recent (1 month) use
of opiates, antidepressants or other psychoactive medications including
antiepileptics, or significant physical comorbidity (minor self-limiting illnesses
were permitted) as assessed by history and physical examination and
contraindications to PET or MRI scanning.
Subjects underwent a screening assessment, which included medical and
psychiatric history as well as the history of alcohol, tobacco and other substance use
and a physical examination. A urine drug screen was carried out on the scan day to
exclude psychoactive drug use. Negative symptom severity was assessed using the
scale for the Assessment of Negative Symptoms (SANS)73. In addition, the physical
and social anhedonia rating scale74, and temporal experience of pleasure scale
(TEPS) were administered to the participants to assess anhedonia. The Calgary
depression scale was used to assess depression75.
Genotyping. Previous studies have shown that carriers of the OPRM1 G allele
(rs1799971) show reduced [11C]-carfentanil binding44,76. In view of this, venous
blood samples were taken for genotyping for the OPRM1 A118G polymorphism
and were analysed by LGC Limited (Middlesex, UK). DNA was extracted, nor-
malised and underwent SNP-specific KASPTM assay mix. Loci with a call rate <
90% were not included. Subjects were categorised as a G-allele carrier (G: A/ G: G)
or not (A: A).
Structural MRI acquisition. High resolution T1 weighted volumes were acquired
using a 3T MR scanner (Magneton Trio Syngo MR B13 Siemens 3T; Siemens AG,
Germany) and a magnetisation prepared rapid gradient echo (MPRAGE) sequence
(TR= 2300 ms, TE= 2.98 ms, TI= 900 ms, flip angle= 9°, field of view= 256
mm, image matrix= 240 × 256) with a resolution of 1 mm isotropic. For the
volume, 160 abutting straight sagittal slices were collected in an interleaved right to
left manner, resulting in whole head coverage. Parallel imaging using Generalized
Auto calibrating Partially Parallel Acquisition (GRAPPA) with an acceleration
factor of 2 was performed.
PET acquisition. [11C]-carfentanil, a selective MOR agonist, was synthesised by
labelling its des-methyl precursor (4-Piperidinecarboxylic acid, 4-[(1-oxopropyl)
phenylamino]-1-(2-phenylethyl), sodium salt; ABX Advanced Biochemical Com-
pounds, Radeberg, Germany/ Pharmasynth, Tartu, Estonia), with carbon-11 using
a modification of a previously described method77 on a semi-automated Modular
Lab Multifunctional Synthetic Module (Eckert & Ziegler, Berlin, Germany). The
final product was reformulated in sterile 0.9% saline containing ∼10% ethanol (v/v)
and satisfied quality control criteria for specific activity and purity before being
injected intravenously as a slow bolus over ∼20 s. Following a transmission CT
scan, a maximum of 300MBq of [¹¹C]-carfentanil was administered. PET emission
data were collected for 90 min in 26 frames (8 × 15 s, 3 × 60 s, 5 × 120 s, 5 × 300 s
and 5 × 600 s, to a total of 5400 s). PET scans were acquired on a Siemens HiRez 6
PET/computed tomography scanner (Siemens Healthcare, Erlangen, Germany).
PET image analysis. Image pre-processing and PET modeling were carried out
using MIAKAT™ software (www.miakat.org). Dynamic PET data were corrected
for attenuation and scatter, and for motion by frame-by-frame realignment to
frame 16. Each scan was rigid-body coregistered to the structural MRI. ROIs were
defined using a neuroanatomical atlas78, applied to the PET image by non-linear
deformation parameters derived using unified segmentation of the structural MRI
using statistical parametric mapping software (SPM 12). The template and atlas fits
were confirmed visually for each participant. [11C]-carfentanil binding potential
(BPND) values were quantified using the simplified reference tissue model (SRTM)
with occipital lobe grey matter as the reference41,79. This approach shows good
agreement on comparison with the arterial input function derived volume of
distrbution31,46, and the occipital cortex has negligible MOR availability42,80–83.
We focussed on striatum as our primary region of interest because it plays a key
role in the hedonic response, is rich in MOR84, and studies in schizophrenia show
striatal hypoactivation in response to reward85, and reduced striatal MOR ligand
binding post-mortem27. In addition, studies have shown that a hedonic network,
comprising the orbitofrontal cortex, cingulate cortex, insular cortex, midbrain, and
amygdala as well as the striatum, is activated in response to hedonic stimuli86,
including to social reward20,87. Moreover, a meta-analysis of fMRI studies which
focussed on neural correlates of anhedonia identified hypo-activation of the
cingulate cortex, orbitofrontal cortex, as well as the striatum, during reward tasks in
schizophrenia relative to controls88. In view of this, we conducted a secondary
analysis to test the hypothesis that MOR availability was reduced in schizophrenia
in the hedonic network consisting of the orbitofrontal cortex, cingulate cortex,
insular cortex, midbrain, and amygdala.
To assess if [11C]-carfentanil uptake in the reference tissue differed between
groups, and thus affected global BPND calculations, standardised uptake values
(SUV) were calculated by dividing the tissue radioligand uptake (calculated using
the 10–90 min summed image) by injected dose per body weight.
The gray matter volume of the whole brain and the volumes of the ROIs were
obtained from the individual’s structural MRI scans after tissue segmentation as
follows. The CIC atlas was non-linearly warped into subject space, and normalised
to the subject’s T1 weighted MRI images using SPM12 (SPM; https://www.fil.ion.
ucl.ac.uk/spm/software/spm12/). After tissue segmentation also using SPM12, the
grey matter volume for each ROI in the CIC atlas was then extracted as the volume
of each ROI weighted by the grey matter probability.
MOR covariance analysis. In addition to regional alterations, it remains unknown
if global brain MOR organisation is altered in schizophrenia. To assess this, we
performed a correlation analysis for the whole brain and compared this for the two
groups89. Within each group, the correlation coefficients between [11C]-carfentanil
BPND at each ROI with all other ROIs (125 ROIs defined in the Clinical Imaging
Centre atlas78) were calculated and z values derived using the Fisher z-
transformation to derive a global correlation matrix. This matrix was considered as
a covariance network, where nodes are the ROIs and interregional correlations
are the edges. The matrix consisted of 7750 edges. To determine the difference in
the strength of connectivity of the edges between patient and control groups, each
edge within these networks was compared between groups using permutation
testing in MATLAB (100,000 permutations of group labels). To correct for the
large number of partially dependent comparisons, the network-based statistic was
used, with a primary threshold of alpha= 0.0590. To identify primary contributors
to the effect between groups, we conducted a further analysis using a more con-
servative threshold, alpha= 0.001, consistent with the approach used in previous
imaging studies using network-based stastistics35,89.
Statistical analysis. Statistical analysis was performed with SPSS (version 20) for
MAC OS X and Graph pad prism version 7.04. Normality of distribution was
tested using the Shapiro-Wilk test. The main hypothesis that there was a group
difference in the MOR availability in the striatum was tested using an independent
sample t-test. To determine whether there was an effect of group on BPND values of
the hedonic network, we performed two way-ANOVA with BPND as the dependent
variable and group (patient or control) as the independent variable. We examined
correlations between PET and clinical data using Pearson’s r. All data are presented
as mean ± SEM, and the level α was set for all comparisons at P < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data and code used in the production of this manuscript are available on request.
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